rss
Br J Ophthalmol 2006;90:496-500 doi:10.1136/bjo.2005.072777
  • Laboratory science - Extended reports

Vascular effects on ciliary tissue from endoscopic versus trans-scleral cyclophotocoagulation

  1. S C Lin1,
  2. M J Chen2,
  3. M S Lin1,
  4. E Howes1 and
  5. R L Stamper1
  1. 1Department of Ophthalmology, University of California, San Francisco, San Francisco, CA, USA
  2. 2Department of Ophthalmology, Taipei Veterans General Hospital, National Yang-Ming University, Taiwan, Republic of China
  1. Correspondence to: Shan Chi Lin MD, Department of Ophthalmology, University of California, San Francisco, 10 Koret Way, San Francisco, CA 94143, USA; lins{at}vision.ucsf.edu
  • Accepted 17 October 2005

Abstract

Aim: To determine the acute and chronic vascular effects of endoscopic cyclophotocoagulation (ECP) versus trans-scleral cyclophotocoagulation (TCP) in a rabbit model.

Methods: 20 rabbits underwent ECP in one eye and another 20 rabbits had unilateral TCP. Five treated eyes from each group underwent endoscopic fluorescein angiography (EFA) of the treated ciliary processes at each of the following time points: immediate, 1 day, 1 week, and 1 month. Five untreated rabbits were used as controls. The NIH Image software program was used to trace ciliary processes in order to determine their mean intensity, as a measure of their perfusion. Histopathology was also performed on eyes from each time point.

Results: Immediately and 1 day after laser, both TCP and ECP eyes demonstrated severely reduced or non-existent blood flow in the areas of treatment. TCP treated processes essentially remained non-perfused at the 1 week and 1 month time points. ECP treated processes showed some reperfusion at 1 week and greater reperfusion by 1 month. Histopathology confirmed the overall greater vascular occlusion seen with TCP.

Conclusions: Chronic poor perfusion of the ciliary body after TCP may account, in part, for its efficacy, as well as the significant complications including hypotony and phthisis. Late reperfusion of this region after ECP may provide some insight into the differences in efficacy and complication rates compared to TCP.

Notes

  • Grant support: That Man May See, Inc, San Francisco, CA; Research to Prevent Blindness, Los Angeles, CA, USA.

  • Competing interests: SL has received honoraria for speakerships for Medtronics, Inc.

  • The authors do not have a financial/proprietary interest in any of the devices, equipment, instruments, or drugs discussed in this article.

    The results of this study have been presented at the Association for Research in Vision and Ophthalmology (ARVO) meeting in Fort Lauderdale, FL, USA, May, 2002.

This Article

  1. Abstract
  2. Full text
  3. PDF

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.